CIPLA LTD vs DR. REDDY S LABORATORIES

A side-by-side comparison of CIPLA LTD (CIPLA) and DR. REDDY S LABORATORIES (DRREDDY) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

CIPLA LTD and DR. REDDY S LABORATORIES are evenly matched on the numbers (77). The breakdown below shows where each one wins.

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
24.09
3.42
P/B ratio
2.96
0.90%
Dividend yield
0.59%
₹48.02
EPS
₹50.27

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
11.80%
15.00%
Return on capital
14.00%
21.00%
EBITDA margin
19.00%
13.71%
Net margin
12.34%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
10.96%
10.88%
Profit CAGR (3Y)
-2.65%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹1.01L Cr
₹28,163 Cr
Revenue
₹33,700 Cr
₹3,862 Cr
Net profit
₹4,158 Cr
0.02
Debt / equity
0.20
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
DR. REDDY S LABORATORIES
  • + ["Company's working capital requirements have reduced from 85.1 days to 67.8 days"]
  • ["Dividend payout has been low at 13.2% of profits over last 3 years"]
CIPLA LTD full analysis DR. REDDY S LABORATORIES full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.